Vertex Pharmaceuticals Incorporated... (VRTX)
56
  • CONTENT
  • SOURCES
Vertex to Present New Data at European and North American Virtual Cystic Fibrosis Conferences Highlighting Long-Term Use of CFTR Modulators
BOSTON--(BUSINESS WIRE)-- #ECFS2020--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data from the company’s portfolio of cystic fibrosis (CF) medicines will be presented at the 43rd European Cystic Fibrosis Digital Conference (ECFS) held September 24-25, 2020 and the 2020 North American Cystic Fibrosis Virtual Conference (NACFC) taking place October 7-23, 2020. An oral presentation at the ECFS Digital Conference will highlight, for the first time, interim results from the TRIKAFTA
GOLDMAN SACHS: Buy these 21 stocks on track for years of market-beating growth that could make them future giants — even rivals to the FAANGs
Summary List Placement These days it's hard to picture a stock market that isn't dominated by Big Tech. But two decades ago, who imagined a market where GE and Exxon were almost afterthoughts? The amount of money invested in Apple, Amazon, Microsoft, Alphabet, and Facebook today is staggering, as Goldman Sachs Chief US Equity Strategist David Kostin says the stock market hasn't been this top-heavy in 40 years. But it will change one day, and Kostin says people are hungry for the next big thing. "Investors are increasingly searching for fast-growing firms beyond the 'current five,'" he wrote. Finding those potential replacements starts with a focus on the incredible growth that made those five companies so successful. "The ability of these firms to grow sales rapidly regardless of the economic situation has been brought into focus by the corona crisis," he said. "Growth is particularly important with interest rates at the lower bound. " So Kostin and his team applied their " Rule of Ten " framework and sought companies that reported annual revenue growth of at least 10% in 2018 and 2019, and are expected to maintain that level in 2021 and 2022.
Why One Analyst Thinks That Dell Is Undervalued
Also, Wall Street views on Sirius XM, Equinix, Aaron’s, Vertex Pharmaceuticals, IMAX, and First Republic Bank.
Big Tech Weighs Too Much on the S&P 500. Feast on These Stocks Instead.
The allure of Autodesk, Intuitive Surgical, PayPal, Vertex Pharmaceuticals, ServiceNow, and some small-cap funds. Also, Blackstone boss Steve Schwarzman’s take on the future of cities.
European advisory group backs expanded use of Vertex's Kalydeco (NASDAQ:VRTX)
The European Medicines Agency's advisory group CHMP has adopted a position opinion backing the use of Vertex Pharmaceuticals' (NASDAQ:VRTX) Kalydeco (ivaca
The Daily Biotech Pulse: Moderna Inks 2 R&D Deals, BioNTech To Buy Manufacturing Facility, Dyne Therapeutics IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) (the first subject has been dosed in a Phase 3 trial evaluating etrasimod for the potential treatment of moderately to severely active ulcerative colitis) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) (announced a deal with Russia for 100 million doses of Sputnik-V vaccine against the coronavirus) Fortress Biotech (NASDAQ: FBIO ) Guardant Health Inc (NASDAQ: GH ) Immunovant Inc (NASDAQ: IMVT ) Insmed Incorporated (NASDAQ: INSM ) InVitae Corp (NYSE: NVTA ) Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Myokardia Inc (NASDAQ: MYOK ) Nevro Corp (NYSE: NVRO ) Novocure Ltd (NASDAQ: NVCR ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) RedHill Biopharma Ltd (NASDAQ: RDHL ) Revance Therapeutics Inc (NASDAQ: RVNC ) SI-Bone Inc (NASDAQ: SIBN ) Silk Road Medical Inc (NASDAQ: SILK ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 16) PainReform Ltd (NASDAQ: PRFX ) Pandion Therapeutics Inc (NASDAQ: PAND ) SILENCE THERAPE/S ADR (NASDAQ: SLN ) Stocks In Focus Moderna Announces 2 R&D Collaborations For Up To $880M Moderna Inc (NASDAQ: MRNA ) and Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) announced a three-year strategic research collaboration and licensing agreement aimed at the discovery and development of lipid nanoparticles and mRNAs for the delivery of gene-editing therapies for cystic fibrosis.
Moderna expands cystic fibrosis partnership with Vertex Pharma (NASDAQ:MRNA)
Moderna (NASDAQ:MRNA) inks a research collaboration and licensing agreement with Vertex Pharmaceuticals (NASDAQ:VRTX) aimed at the discovery and developmen
Thinking about buying stock in Delta Air Lines, Scientific Games, GameStop, Vertex Pharmaceuticals, or Fortress Biotech?
NEW YORK, Sept. 14, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DAL, SGMS, GME, VRTX, and FBIO. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
EC validates Vertex's marketing application for expanded use of Kaftiro + Ivacaftor (NASDAQ:VRTX)
The European Medicines Agency (EMA) has validated Vertex Pharmaceuticals' (NASDAQ:VRTX) Type II Variation Marketing Authorization Application for the expan
Vertex Announces European Medicines Agency Type II Variation Marketing Authorization Application Validation for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination with ivacaftor in People with One Copy of the F508del Mutation
LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the European Medicines Agency (EMA) has validated a Type II Variation Marketing Authorization Application (MAA) for the expanded indication of KAFTRIO®* (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor to treat CF in patients ages 12 years and older with at least one copy of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. If approved, eligible
Top 6 Biotech Stocks For Traders
If you’re up for some speculative biotech trades, we are presenting the top 6 among our freshest picks of biotech stocks for the coming 12 months.
Follow Us